News
Published Data as of
In the STEP Young trial, body mass index (BMI) fell 17.4% at 68 weeks in children aged 6 to under 12 on semaglutide. It rose 2.2% in children on placebo.1 The New England Journal of Medicine published the results on November 16, 2026.2,3 Novo Nordisk states semaglutide is not approved in the United States for children under 12.3 PepBank holds 934 publications with findings in people for semaglutide.4
STEP Young is a phase 3, randomized, double-blind, placebo-controlled trial in 167 children aged 6 to under 12 with obesity.1,3 Of these, 112 children were assigned to semaglutide and 55 to placebo.2 Children received once-weekly semaglutide, with a top amount set by baseline body weight.3
Novo Nordisk reported that BMI fell 17.4% with semaglutide and rose 2.2% with placebo at 68 weeks. The estimated difference was 19.7 percentage points.1,3 Counting children who stopped treatment, Wegovy lowered BMI by an estimated 16.2 percentage points more than placebo.1
| Measure | Semaglutide | Placebo |
|---|---|---|
| Change in BMI at 68 weeks | Fell 17.4% | Rose 2.2%1 |
| Drop in BMI category at week 68 | 79% of children | 23% of children2 |
| No longer classified as having obesity at week 68, if all followed the treatment and used no other weight-management interventions | 40.4% of children | 0% of children3 |
At week 68, 79% of children on semaglutide moved to a lower BMI category, compared with 23% on placebo.2 If all children followed the treatment and used no other weight-management interventions, 40.4% on semaglutide were no longer classified as having obesity. This compared with 0% on placebo. Regardless of adherence, the figure was 38.4%.3
Adverse events occurred in 96% of children on semaglutide and 93% of children on placebo.2 The safety and tolerability profile matched earlier semaglutide trials in children and adults, with no unexpected safety concerns.3 Novo Nordisk said it observed no safety concerns related to growth or pubertal development.1
Novo Nordisk states semaglutide is not approved in the United States for children under 12.3 The U.S. Food and Drug Administration (FDA) approved Wegovy in 2021. The drug reduces and maintains body weight in adults with obesity. It does the same in pediatric patients 12 years and older with obesity.1,5
In a trial in adults with cardiovascular disease and overweight or obesity but no diabetes, semaglutide reduced the primary cardiovascular end point versus placebo. The hazard ratio was 0.8.6 In trials in people with chronic kidney disease (CKD) or atherosclerotic cardiovascular disease, semaglutide reduced first kidney composite events versus placebo. The hazard ratio was 0.84.7
As of November 15, 2026, PepBank holds 934 publications with findings in people for semaglutide, with 4515 findings in people.4 By evidence class, it also holds 20 publications with findings in animals and 3 with findings in cells or tissue. A computer model predicted the findings in 13 more.4 Among the peptides in PepBank, semaglutide has 663 registered trials in its records.4
PepBank holds 966 semaglutide studies that gave the peptide and reported results. Those studies hold 4624 results.4
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated